Impact ofKRAS,BRAF,PIK3CA,TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases

Effect of liver regeneration on malignant hepatic tumors

(2016) Ji-Hua Shi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

(2015) N. Normanno et al.   ANNALS OF ONCOLOGY

Meta-analysis ofKRASmutations and survival after resection of colorectal liver metastases

(2015) K. W. Brudvik et al.   BRITISH JOURNAL OF SURGERY

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

(2015) Nicholas McGranahan et al.   CANCER CELL

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

(2015) Lucy R Yates et al.   NATURE MEDICINE

High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer

(2015) Iain Tan et al.   GENOME BIOLOGY

Concordant analysis of KRAS, BRAF, PIK3CA mutations and PTEN expression between primary colorectal cancer and matched metastases

(2015) Chen Mao et al.   Scientific Reports

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

(2014) F. Ciardiello et al.   ANNALS OF ONCOLOGY

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

(2014) Rona Yaeger et al.   CANCER

Genetic and Phenotypic Diversity in Breast Tumor Metastases

(2014) V. Almendro et al.   CANCER RESEARCH

TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon

(2014) Filippo Pietrantonio et al.   ONCOLOGY

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens

(2014) Inger Marie Løes et al.   TUMOR BIOLOGY

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

(2013) Georgios Karagkounis et al.   CANCER

High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma

(2013) Edmund A. Mroz et al.   CANCER

Changing patterns of recurrent disease in colorectal cancer

(2013) I. Grossmann et al.   EJSO

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

(2013) Bernard Nordlinger et al.   LANCET ONCOLOGY

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983)

(2012) Halfdan Sorbye et al.   ANNALS OF SURGERY

Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas

(2012) Efsevia Vakiani et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

(2012) Hao-Wei Teng et al.   JOURNAL OF SURGICAL ONCOLOGY

Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment

(2011) J. S. Vermaat et al.   CLINICAL CANCER RESEARCH

Allele-specific copy number analysis of tumors

(2010) P. Van Loo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

(2009) Myrddin Rees et al.   ANNALS OF SURGERY

KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

(2009) Garrett M. Nash et al.   ANNALS OF SURGICAL ONCOLOGY

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

(2008) Birgit Gruenberger et al.   BMC CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

(2008) Ranjan Chrisanthar et al.   PLoS One